Anti-CD40L prevents meningeal B cell aggregates and mitigates progressive autoimmune encephalomyelitis.
Anti-CD40L treatment may be an effective intervention to mitigate progressive immunopathology associated with meningeal TLS, and modulates and likely silences other CD40-dependent antigen-presenting cells in the CNS, including myeloid cells and astrocyte subsets.